For men whose prostate cancer has outrun hormone therapy, treatment options narrow sharply and survival odds remain grim. A newly identified molecular mechanism — and the antibodies designed to block it — could represent a fundamentally different way to interrupt the cascade that drives the deadliest form of the disease, without the toxicity profile that limits standard chemotherapy.
At the center of this research is a proteolytic cleavage event involving two proteins that collaborate to fuel metastatic castration-resistant prostate cancer (mCRPC). The metalloprotease ADAM17 cleaves the TGF-β type I receptor (TβRI) at the cell surface, liberating a soluble intracellular domain — designated TβRI-ICD — that migrates into the nucleus. Once there, it drives epithelial-to-mesenchymal transition (EMT), the cellular reprogramming that enables tumor cells to detach, invade surrounding tissue, and colonize distant organs. Crucially, high TGFBR1 expression correlated with poor survival in two independent mCRPC patient cohorts, and TGFBR1 levels tracked closely with ADAM17 expression, suggesting the two proteins operate as a co-regulated oncogenic unit. A panel of fully human monoclonal antibodies engineered to sterically block the ADAM17 cleavage site effectively prevented TβRI-ICD nuclear accumulation, suppressed EMT markers, and reduced both primary tumor growth and metastatic spread in an orthotopic mouse model — with efficacy comparable to docetaxel.
This work is notable for several reasons beyond efficacy data alone. TGF-β signaling has long been recognized as a double-edged sword in oncology — tumor-suppressive early, pro-metastatic late — making it a frustratingly difficult therapeutic target. By focusing on a specific downstream cleavage event rather than broadly silencing TGF-β, this approach sidesteps some of the pathway's complexity. That said, the evidence remains preclinical: mouse models, even orthotopic human-cell models, have a poor track record of predicting human drug response, particularly for metastatic disease. The absence of overt cardiovascular or weight-loss toxicity in immunodeficient mice is encouraging but far from sufficient reassurance. The dual-cohort survival correlation strengthens the biological rationale, but causality requires prospective clinical validation. If these antibodies advance into human trials and retain their efficacy-to-toxicity profile, they could offer a genuinely differentiated option in a space where therapeutic resistance is nearly inevitable.